Navigation Links
Old drug may point the way to new treatments for diabetes and obesity

ANN ARBOR Researchers at the University of Michigan's Life Sciences Institute have found that amlexanox, an off-patent drug currently prescribed for the treatment of asthma and other uses, also reverses obesity, diabetes and fatty liver in mice.

The findings from the lab of Alan Saltiel, the Mary Sue Coleman director of the Life Sciences Institute, are scheduled to be published online Feb. 10 in the journal Nature Medicine.

"One of the reasons that diets are so ineffective in producing weight loss for some people is that their bodies adjust to the reduced calories by also reducing their metabolism, so that they are 'defending' their body weight," Saltiel said. "Amlexanox seems to tweak the metabolic response to excessive calorie storage in mice."

Different formulations of amlexanox are currently prescribed to treat asthma in Japan and canker sores in the United States. Saltiel is teaming up with clinical-trial specialists at U-M to test whether amlexanox will be useful for treating obesity and diabetes in humans. He is also working with medicinal chemists at U-M to develop a new compound based on the drug that optimizes its formula.

The study appears to confirm and extend the notion that the genes IKKE and TBK1 play a crucial role for maintaining metabolic balance, a discovery published by the Saltiel lab in 2009 in the journal Cell.

"Amlexanox appears to work in mice by inhibiting two genesIKKE and TBK1that we think together act as a sort of brake on metabolism," Saltiel said. "By releasing the brake, amlexanox seems to free the metabolic system to burn more, and possibly store less, energy."

Using high-throughput chemical screening at LSI's Center for Chemical Genomics to search for compounds that inhibit IKKE and TBK1, the researchers hit upon an approved off-patent drug: amlexanox. They then demonstrated that amlexanox had profound beneficial effects in both genetic and dietary-induced obese mice. The chemical lowered the weight of obese mice and reversed related metabolic problems such as diabetes and fatty liver.

"These studies tell us that, at least in mice, the IKKE/TBK1 pathway plays an important role in defending body weight by increasing storage and decreasing burning of calories, and that by inhibiting that pathway with a compound, we can increase metabolism and induce weight loss, reverse diabetes and reduce fatty liver," Saltiel said.

The drug has been on the market in Japan for more than 25 years.

However, the researchers don't yet know if humans respond with the same pathway, or if the discovery of amlexanox's effectiveness in mice can lead to a compound that is safe and effective for treating obesity and diabetes in humans.

"We will be working hard on that," Saltiel said.


Contact: Laura J. Williams
University of Michigan

Related biology news :

1. Bluemetal Architects appoints David Le Penske as Vice President of Health & Life Sciences
2. Summit of osteoporosis experts from CIS countries issue 5-point call for action
3. Scientists pinpoint molecular signals that make some women prone to miscarriage
4. Serendipity points to new potential target and therapy for melanoma
5. Research pinpoints key gene for regenerating cells after heart attack
6. Fish ear bones point to climate impacts
7. Protein injection points to muscular dystrophy treatment
8. University of Maryland School of Medicine, NIH study pinpoints brain areas role in learning
9. New study to examine ecological tipping points in hopes of preventing them
10. Fossil study helps pinpoint extinction risks for ocean animals
11. Remarkable enzyme points the way to reducing nitric acid use in industry
Post Your Comments:
(Date:6/21/2016)... 2016 NuData Security announced today that Randy ... principal product architect and that Jon Cunningham ... development. Both will report directly to Christopher ... reflect NuData,s strategic growth in its product and ... demand and customer focus values. ...
(Date:6/9/2016)... , June 9, 2016 ... Police deploy Teleste,s video security solution to ensure the safety ... France during the major tournament Teleste, ... communications systems and services, announced today that its video security ... to back up public safety across the country. ...
(Date:6/2/2016)... , June 2, 2016 Perimeter ... Platforms, Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... market will generate revenues of $17.98 billion in 2016. ... DVTEL Inc, a leader in software and hardware technologies ...
Breaking Biology News(10 mins):
(Date:6/27/2016)...  Alex,s Lemonade Stand Foundation (ALSF), a leading national ... a state-of-the-art bioinformatics lab, using ,big data, to advance ... as Liz Scott , co-executive director of ALSF ... in Washington, D.C. , hosted by ... advocate of pediatric cancer research and awareness. ...
(Date:6/27/2016)...  Global demand for enzymes is forecast to ... $7.2 billion.  This market includes enzymes used in ... production, animal feed, and other markets) and specialty ... and beverages will remain the largest market for ... products containing enzymes in developing regions.  These and ...
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... , June 27, 2016  Sequenom, Inc. (NASDAQ: ... to enabling healthier lives through the development of innovative ... of the United States denied ... that the claims of Sequenom,s U.S. Patent No. 6,258,540 ... eligibility criteria established by the Supreme Court,s Mayo Collaborative ...
Breaking Biology Technology: